Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. - Wikidata - thesis-toulmin - TriplyDB

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.

http://www.wikidata.org/entity/Q34051790

about

The fate of chemoresistance in triple negative breast cancer (TNBC)Role of positron emission tomography for the monitoring of response to therapy in breast cancer Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer.Positron Emission Tomography (PET) in Oncology Targeting lactate transport suppresses in vivo breast tumour growth Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.The current status of positron emission mammography in breast cancer diagnosis.[¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression.Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.Ultrasonic RF time series for early assessment of the tumor response to chemotherapy.Early detection of chemotherapy-refractory patients by monitoring textural alterations in diffuse optical spectroscopic images.FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.

P2860

Q26775232-AE17CED0-557D-4AD1-A08C-39A0DDB591F5 Q28080621-6AB2E202-7040-4BBF-97C8-4434CE862357 Q34502227-369616B0-5621-4EA9-B1CF-4AC41B0E26A3 Q34774840-D99156B3-96F7-4904-A937-0B3972E74E7E Q36326353-C4AA13D0-BB0B-4DFF-8775-613D8EBC7584 Q36399789-95EE67B4-63FC-436D-B2E4-F264A4582667 Q36557319-36399B38-19E1-438D-9F9D-B799C6D06A4F Q36653693-5499F9A2-1D92-47D6-AD47-0F02150B7EB4 Q37254082-256B9BAE-5A65-47F0-B9BE-82D6EA960BAB Q38067336-AC615129-6D5A-4E5E-9088-6814B0DF3D84 Q38077874-8CBA0B16-0FE6-4F2D-A85E-80A23DDB6AD3 Q38090509-7E8C4510-C0E2-4E07-AB4A-1F68E21017C8 Q38165388-D2108CF9-4926-42B1-B18E-A9C73F63CBF1 Q38451966-0344F9DB-963E-40D6-8A30-3F87B6CBF1A8 Q38461102-A2F0E154-F2B8-4664-9F25-A0EE62C71BDB Q38465712-308EF589-F50C-4561-B64B-735DCE6BB9B8 Q39311162-49D4CFB0-429F-401A-888F-6710DA5D2690 Q49989966-95F042DA-CAB8-4BDE-8A5D-5BA6E6B05FA8 Q50782447-C0E76DC9-4B9A-462F-AEDD-85B4751DCF04 Q51347358-D570056E-02FD-432B-B643-3F9F6480F7C0

P2860

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.

http://www.wikidata.org/entity/Q34051790

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Early metabolic response using ...... with neoadjuvant chemotherapy.

@ast

Early metabolic response using ...... with neoadjuvant chemotherapy.

@en

Early metabolic response using ...... with neoadjuvant chemotherapy.

@nl

type

label

Early metabolic response using ...... with neoadjuvant chemotherapy.

@ast

Early metabolic response using ...... with neoadjuvant chemotherapy.

@en

Early metabolic response using ...... with neoadjuvant chemotherapy.

@nl

prefLabel

Early metabolic response using ...... with neoadjuvant chemotherapy.

@ast

Early metabolic response using ...... with neoadjuvant chemotherapy.

@en

Early metabolic response using ...... with neoadjuvant chemotherapy.

@nl

P1433

Q34051790-1E93BB02-955C-48EB-B6D9-A46B0795ED39

P1476

Q34051790-EDD0FE0A-3CCE-447B-A0DA-5F58126D1454

P2093

Q34051790-0A64E131-5845-49FE-BBC9-52D0D54AE759

Q34051790-0B49F3C9-3F9B-461D-8E07-D586756105BC

Q34051790-25C35D5C-6CAE-407E-B7D3-DE2BB2910423

Q34051790-344AFBC0-65D8-4C0D-91DA-82B32FD3D961

Q34051790-36A1A6C9-92D6-4B6A-8DB9-69448D6E0303

Q34051790-378BB90F-8112-45F4-BB56-D94AAA933293

Q34051790-5273FE2B-FB13-4CCE-BECD-3A2AE5817F68

Q34051790-69937348-F455-40E5-A68E-FCAE84F43541

Q34051790-A0EB2329-49B6-47DE-9644-C9E63D6D1E0E

Q34051790-D2ECA88C-987F-482C-B125-32301C18D7A5

P2860

Q34051790-0B2C7FB3-A051-4DEA-9328-E4C799ABAC20

Q34051790-0BB2120A-C3F3-47B9-9254-C8DA82678FE5

Q34051790-15806789-1E20-40E1-9196-B09B06D9A6CE

Q34051790-1E5E8388-7927-491F-B8D7-423B5EDE7F11

Q34051790-202131C7-E81D-4225-AB86-C8AF493A3B31

Q34051790-28CBE4BD-DDCC-44F4-93BD-5EDB13396629

Q34051790-297652EA-607C-4CC2-AB64-C31B1203FC51

Q34051790-2DA9E256-4037-4FD5-A0ED-A7D414B49AD9

Q34051790-2F0D11BA-811F-4A83-8698-F5AEDD9ECEAE

Q34051790-42999596-2432-43D4-A690-FDF54EA759D4

P2888

Q34051790-BBD2B9B1-88AE-416A-8168-A4D91CD3C871

P304

Q34051790-C1A7C5EE-C77E-4BAF-9CE0-0676B7DA83BA

P31

Q34051790-EE00BA85-E216-49FB-995D-54E51E722108

P356

Q34051790-0E2460A8-AB81-4C8C-9D1F-C1596BFA2D39

P407

Q34051790-94EE6288-7471-4C88-9558-F7B89D8983B2

P478

Q34051790-5352932D-6645-4B39-8E54-A2C64ACA14F3

P50

Q34051790-591476FA-8831-4994-B26E-4C61345FCDCD

P577

Q34051790-661C29C2-9973-4129-9710-FB700CE32E1E

P5875

Q34051790-3BEEC579-2F1D-4415-8C84-5627F332EF1F

P6179

Q34051790-418A44A9-B879-459A-BB79-94B30A5E7AA1

P698

Q34051790-05347866-5164-4E47-80FA-AE927AEBD981

P921

Q34051790-97D7DCEA-8716-4F75-82FF-D0D3764415DF

P932

Q34051790-35FE8188-9303-40D7-AE19-7C22B1E55361

P356

1471-2407-11-452

P1433

P1476

Early metabolic response using ...... with neoadjuvant chemotherapy.

@en

P2093

Bhumsuk Keam

http://www.w3.org/2001/XMLSchema#string

Do-Youn Oh

http://www.w3.org/2001/XMLSchema#string

In Ae Park

http://www.w3.org/2001/XMLSchema#string

Jee Hyun Kim

http://www.w3.org/2001/XMLSchema#string

June-Key Chung

http://www.w3.org/2001/XMLSchema#string

Keon Wook Kang

http://www.w3.org/2001/XMLSchema#string

Nariya Cho

http://www.w3.org/2001/XMLSchema#string

Sae-Won Han

http://www.w3.org/2001/XMLSchema#string

Seock-Ah Im

http://www.w3.org/2001/XMLSchema#string

Tae-You Kim

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

Locally advanced breast cancer.

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations.

Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.

Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.

P2888

1471-2407-11-452

P304

452

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-452

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51730318

http://www.w3.org/2001/XMLSchema#string

P6179

1008717023

http://www.w3.org/2001/XMLSchema#string

P698

22011459

http://www.w3.org/2001/XMLSchema#string

P921

P932

3224348

http://www.w3.org/2001/XMLSchema#string